OS Therapies (OSTX) Assets Average (2024 - 2026)
OS Therapies' (OSTX) quarterly Assets Average came in at $7.1 million in Q1 2026, up 44.44% YoY from $4.9 million in Q1 2025, and down 10.47% on a QoQ basis from $7.9 million in Q4 2025.
OS Therapies (OSTX) Assets Average (2024 - 2026) Analysis & Trends
OS Therapies (OSTX) has 3 years of Assets Average data on file, last reported at $7.1 million in Q1 2026.
- Quarterly Assets Average rose 44.44% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 44.44% YoY) and the FY2025 annual result came in at $6.2 million, up 95.34% from the prior year.
- Assets Average declined to $7.1 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $9.6 million in Q3 2025 to a low of $923503.0 in Q1 2024.
- A 3-year average of $4.9 million and a median of $4.9 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average surged 508.93% — and 2026, when it surged 44.44%.
- Tracing OSTX's Assets Average over 3 years: stood at $3.8 million in 2024, then soared by 110.12% to $7.9 million in 2025, then dropped by 10.47% to $7.1 million in 2026.
- The last three Assets Average figures came in at $7.1 million (Q1 2026), $7.9 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 8.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.07 Mn |
| Dec 31, 2025 | 7.90 Mn |
| Sep 30, 2025 | 9.63 Mn |
| Jun 30, 2025 | 7.28 Mn |
| Mar 31, 2025 | 4.89 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 923,503.00 |